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The outcomes of three-dimensional conformal radiotherapy for
early-stage non-small-cell lung cancer patients eligible and
ineligible for stereotactic body radiotherapy
Wyniki konformalnej radioterapii chorych na niedrobnokomórkowego raka płuca
we wczesnym stopniu zaawansowania spełniających kryteria oraz
niespełniających kryteriów kwalifikacji do napromieniania stereotaktycznego
Abstract
Introduction: Stereotactic body radiotherapy (SBRT) in early-stage non-small-cell lung cancer (NSCLC) results in promising
outcomes, comparable with the outcomes of surgery. However, not all such patients are good candidates for this treatment.
We conducted a retrospective evaluation of the outcomes of three-dimensional conformal radiotherapy (3D-CRT) in patients
with stage I/II NSCLC with a special focus on the outcomes of patients who were eligible for SBRT but received 3D-CRT due
to the unavailability of the former.
Material and methods: We evaluated 132 consecutive patients with stage I/II NSCLC who had received radical 3D-CRT
between 1998 and 2009. As various radiotherapy schedules had been used, biologically equivalent doses (BEDs) were
calculated for all the patients. A total of 68 patients were eligible for SBRT (peripheral T1-3 N0 tumours < 5 cm in diameter).
Overall survival (OS) and local progression free survival (LPFS) were estimated using Kaplan-Meier methodology for the
entire study population and for the groups eligible and ineligible for SBRT. Univariate and multivariate analyses were
performed for the prognostic factors.
Results: Median BED in the study population was 74 Gy (58–82 Gy). Patients eligible for SBRT had a significantly lower
gross tumour volume (GTV) than the other patients (p < 0.00001). Three-year OS and LPFS were 37% and 50%, respectively.
When we compared patients eligible for SBRT and those ineligible for SBRT the only significant difference was for three-year
LPFS (58% v. 35%, p = 0.04). Multivariate analysis showed that only GTV, performance status and tumour stage were
significantly correlated with local curability.
Conclusions: We showed an improved local control following 3D-CRT in patients eligible for SBRT compared to the other
patients. However, also in these cases, local control was inferior compared to the outcomes of SBRT reported in the literature.
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Introduction
Surgery (lobectomy, bilobectomy or pneumo-
nectomy) is the treatment of choice for early-stage
(stage I or II) non-small-cell lung cancer (NSCLC)
and is associated with a 5-year survival of 50–60%
[1]. Brown et al. [2] showed that only 18% of pa-
tients below 65 years of age, 12% of patients aged
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66–75 years and 2% of patients over 75 years of
age were eligible for surgery at diagnosis. Lung
cancer affects the elderly population; more than
50% of patients with NSCLC are over 65 and near-
ly one third are over 70 years of age [3]. In 2005 in
Poland, 42% of patients who had died from lung
cancer were at least 70 years of age [4]. Radiothe-
rapy remains the treatment of choice in NSCLC
patients ineligible for surgery due to non-oncolo-
gic reasons. However, the outcomes of radiothera-
py in early-stage NSCLC remain unsatisfactory
compared to the outcomes of surgery. Five-year
survival and local control following radical radio-
therapy alone for early-stage NSCLC are estimated
at 30% and 50%, respectively [5].
In recent years, the hopes to improve treatment
outcomes in patients with NSCLC ineligible for
surgery, especially in patients with peripheral tu-
mours, are associated with the use of stereotactic
body radiotherapy (SBRT). A systematic review, 5-
year survival in patients undergoing SBRT was
estimated at 47% (range: 18–78%) and local con-
trol at 80–100% [6]. These outcomes are compara-
ble with treatment outcomes in patients undergo-
ing surgery and are far superior than the outcomes
of conventional radiotherapy. Randomised studies
to compare SBRT with surgery and with radiothe-
rapy are, however, lacking. In the case of conven-
tional radiotherapy the patients often have larger
tumours, often centrally located, in which case the
toxicity of SBRT is considerable. Timmerman et al.
[7] administered SBRT to 70 patients with central
tumours and recorded 14 cases of grade 3–5 toxi-
city (6 toxic deaths), which suggests a limitation
of this method in centrally located lung cancers.
Two prospective phase II studies are currently
ongoing and their aim is to compare the outcomes
of conventionally fractionated three-dimensional
conformal radiotherapy (3D-CRT) with the outco-
mes of SBRT, namely an Australian study (TROG
09.02) comparing 3D-CRT at the dose of 60–66 Gy
given in 30–33 fractions versus SBRT at the dose
of 54 Gy in 3 fractions, and a Scandinavian study
(SPACE, Scandinavian Stereotactic Precision and
Conventional Radiotherapy Evaluation) compa-
ring 3D-CRT at the dose of 70 Gy given in 35 frac-
tions versus SBRT at the dose of 45 Gy in 3 frac-
tions.
At our centre, in peripheral tumours, we often
use accelerated hypofractionated 3D-CRT, which
results in a higher biological dose. SBRT is not
available. Given the lack of prospective studies
comparing 3D-CRT versus SBRT, a retrospective
assessment of 3D-CRT outcomes in patients with
NSCLC who would have been potentially eligible
for SBRT but received 3D-CRT with dose escala-
tion also provides important information.
The aim of our study was to perform a retro-
spective assessment of treatment outcomes in pa-
tients with early-stage NSCLC who had received
3D-CRT with a particular focus on patients who
were potential candidates for SBRT.
Material and methods
We evaluated 132 patients with stage I or II
NSCLC according to the UICC TNM classification
(5th and 6th editions) [8] who had received radi-
cal conformal radiotherapy at the Oncology Cen-
tre — Maria Skłodowska-Curie Memorial Institute
in Warsaw, Poland, between 1998 and 2009. Ta-
ble 1 summarises patient characteristics. The pa-
tients met the Centre’s eligibility criteria for radi-
cal radiotherapy, which included: histopathologi-
cal confirmation of NSCLC, Karnofsky performan-
ce status (KPS) of over 70%, no weight loss exce-
eding 10% over 6 months prior to treatment, ade-
quate pulmonary function to be able to undergo
radical radiotherapy and ineligibility for surgical
treatment due to medical reasons or due to refusal
of consent. In very few cases we considered pa-
tients with poor performance status or with a we-
ight loss exceeding 10% due to non-malignant cau-
ses eligible for radical radiotherapy.
In order to stage the tumour each subject un-
derwent the following: clinical examination, blo-
od tests (complete and differential blood cell co-
unts, kidney and liver function tests, coagulation
tests), chest X-rays in the posteroanterior and la-
teral views, a brain CT or MRI scan, and — if di-
stant metastases were being suspected — bone
scintigraphy. Nine patients (7%) had undergone a
baseline PET-CT scan for the purposes of staging
and establishing treatment. Eleven patients (8%),
prior to radiotherapy, had received an average of
3 (range: 2–6) courses of platinum-based chemo-
therapy (cisplatin plus vinorelbine [PN] or carbo-
platin plus vinorelbine [KN]).
Radical radiotherapy regimens in NSCLC
changed several times during the study period. Our
patients received conventional radiotherapy (total
doses of 60–74 Gy in fractions of 2 Gy, 5 days a
week), accelerated hyperfractionated radiotherapy
(total dose of 60 Gy in fractions of 1.5 Gy, 3 times
a day, 15 fractions a week) or various forms of ac-
celerated hypofractionated radiotherapy (from a
mild hypofractionation of 66 Gy in fractions of 2.2
Gy given 5 times a week through a total dose of
56.7 Gy in fractions of 2.7 Gy given 5–6 times a
week, to a total dose of 48–52 Gy in fractions of 4
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Table 1. Patients’ characteristics
Characteristic Number (percent) of patients
Sex
Male 103 (78)
Female 29 (22)
Age (years) Median: 71,5 (range: 51–89)
Karnofsky performance status (KPS)
90%–100% 50 (38)
70%–80% [w tym/including: 70] 82 [17] (62)
Weight loss in the previous 6 months
> 10% 2 (1)
5–10% 10 (8)
No weight loss or < 5% 120 (91)
Comorbidities*
Yes 125 (95)
No 7 (5)
Histology
Squamous 58 (44)
Adenocarcinoma 11 (8)
Non-small cell without further specification 59 (45)
No histology 4 (3)
Stage
I 85 (64)
II 47 (36)
T-category
T1 43 (33)
T2 54 (41)
T3 35 (26)
N-category
N0 121 (92)
N1 11 (8)
Side
Right 71 (54)
Left 61 (46)
Lobe
Upper 73 (55)
Middle 9 (7)
Lower 47 (36)
All 3 (2)
Neoadjuvant chemotherapy
Yes 11 (8)
No 121 (92)
*Comorbidities were defined in this study as the need for the permanent drug use because of the chronic disease and/or other malignancy in the history
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Gy given 5 times a week). Elective nodal irradia-
tion (ENI) was employed in the earlier period,
while in the later period ENI was not used in pa-
tients with peripheral tumours and was limited to
the hilum in patients with central tumours. The
radiotherapy regimens used in our patients are
summarised in Table 2.
Only those patients were included in the stu-
dy in whom radiotherapy planning had been con-
ducted entirely with the use of three-dimensional
planning and in whom the requirements of con-
formal radiotherapy had been met. Radiotherapy
planning was conducted in accordance with the
recommendations of the International Commission
on Radiation Units and Measurements (ICRU) Re-
port No. 62 concerning the principles of 3D-CRT
use [9]. The dose was prescribed at the ICRU refe-
rence point. The minimum and maximum doses
to the planning target volume (PTV) were 95%
and 107%, respectively (in cases of large PTV,
delivering a minimum dose of 90% was accepta-
ble). Target volumes were defined in accordan-
ce with the protocol. Gross tumour volume (GTV)
was defined as the tumour or, in the case of N1,
hilar lymph nodes defined on the pulmonary
window. Clinical tumour volume (CTV) was ob-
tained by adding a margin of 5 mm or, in cases
of central tumours, by adding a margin of 5 mm
and the ipsilateral hilum. PTV was established
by adding CTV to an individually selected mar-
gin following previous verification of respirato-
ry mobility in three dimensions on a simulator.
Elective mediastinal irradiation was used in
some patients. The mean dose delivered to the
lungs did not exceed 15 Gy for peripheral tumo-
urs treated with hypofractionated radiotherapy
and 20 Gy for tumours treated using conventio-
nally fractionated radiotherapy. Less than 35%
Table 2. Radiotherapy schedules
Radiotherapy schedule Number (percent)
of patients
Conventional radiotherapy schedule, total dose: 60–74 Gy
Without elective nodal irradiation 32 (24)
With elective nodal irradiation 24 (18)
Accelerated hyperfractionation with elective nodal irradiation
Dose per fraction 1,5 Gy, 3 × daily; total dose 60 Gy 6 (5)
Hypofractionation
Dose per fraction 2,2 Gy; total dose 66 Gy (elective irradiation of ipsilateral hilum) 10 (8)
Dose per fraction 2,7–2,8 Gy; total dose 56,7–58,8 Gy (with elective nodal irradiation) 2 [1] (1)
Dose per fraction 4 Gy; total dose 48–52 Gy (only tumor with margin) 58 (44)
of the lung volume received a dose exceeding
20 Gy. The maximum dose delivered to the spi-
nal cord did not exceed 50 Gy in the case of
conventional fractionation and 36 Gy in the case
of hypofractionation. A nominal energy of pho-
tons X of 6 MV was used and only in exceptio-
nal cases a photon energy of 15 MV was utili-
sed. Normally, 3 to 5 coplanar radiation beams
were used (with the exception of situations
where the field-in-field technique rather than
wedge was used).
In order to compare the total doses given to
the patients with the use of various fraction doses
in various treatment periods we converted the phy-
sical doses into biologically equivalent doses
(BEDs), taking into account treatment durations
and fraction doses. We used the following formu-
la proposed by Fowler [10]:
BED = nd [1 + d (a/b)] – ln2 (T – Tk)
where n is the number of fractions, d is the
fraction dose, T is the total irradiation time, a/b is
the ratio of radiation susceptibility and fraction
dose (which has been assumed to be equal to 10
for lung cancer), Tk is the time after which accele-
rated tumour repopulation (increased tumour pro-
liferation) is observed (which we assumed to be 28
days, according to Fowler).
We retrospectively identified the group of pa-
tients whose tumours met the eligibility criteria for
SBRT. We adopted the Radiation Therapy Onco-
logy Group (RTOG) criteria which define the featu-
res of lung tumours eligible for SBRT using abla-
tion doses, such as 3 × 20 Gy, namely T1–L2 N0
tumours or T3 tumours (chest wall), whose longest
diameter was below 5 cm and whose location was
peripheral (i.e. without any connection with the
mediastinal structures or the pulmonary hili on
imaging studies) [11].
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Figure 1. Overall survival for all patients
The statistical analysis was performed using
Statistica PL (version 6.0). The mean values were
compared using the t-Student test. Overall survi-
val, tumour-related survival, local progression free
survival and distant metastasis free survival were
estimated using Kaplan-Meier methodology and
compared using a log-rank test for the group eligi-
ble for SBRT and the group ineligible for SBRT. All
the survival times were calculated from the date
of radiotherapy commencement. Index events for
the assessment of tumour-related survival inclu-
ded tumour-related death, treatment toxicity and
death from other causes in patients with recurrent
disease. Death from a lung-cancer-unrelated cau-
se without previous disease progression was con-
sidered a censored observation for tumour-related
survival. Isolated regional recurrence (IRR) was
diagnosed if metastases were discovered in previo-
usly uninvolved hilar lymph nodes or mediastinal
or supraclavicular lymph nodes without prior or
concurrent local progression. We evaluated the
effects of potential prognostic factors (KPS, weight
loss, age, sex, possible eligibility for SBRT, histo-
logic type, peripheral versus central location of the
tumour, stage, GTV, radiotherapy regimen, BED)
on overall survival and local progression free su-
rvival using the log-rank test. Overall survival and
local progression free survival were additionally
compared between the group eligible for SBRT and
the group ineligible for SBRT. The factors affecting
these two types of survival in univariate analysis
at the p value of < 0.2 were then included in mul-
tivariate analysis (Cox regression model).
Results
Median follow-up for living patients was 33
months (range: 14–122 months). Median GTV in
the study population was 43 cm3 (range: 3–319
cm3). Median BED in the study population was 74
Gy (range: 58–82 Gy). A total of 68 out of 132 pa-
tients were eligible for SBRT. These patients had
significantly lower mean GTV than did ineligible
patients (36.5 cm3 v. 88.8 cm3, p < 0.00001). Pa-
tients eligible for SBRT received higher doses. The
mean BED values for patients eligible and ineligi-
ble for SBRT were 74.6 Gy and 72.0 Gy, respecti-
vely (p = 0.01).
The estimated 2- and 3-year overall survival
rates were 51% and 37%, respectively, and 95 pa-
tients died during observation. There was 1 toxic
death due to radiation pneumonia 2 months after
treatment. A total of 24 patients (18%) died within
7–89 months following radiotherapy (median: 20
months) from causes unrelated to the underlying
malignancy. The estimated 2- and 3-year tumour-
related survival rates in the study population were
59% and 47%, respectively. The overall survival
curve for the study population is shown in Figure
1. Univariate analysis demonstrated that the follo-
wing factors affected overall survival in a statisti-
cally significant manner: GTV (tumours with GTV
values < 43 cm3 and ≥ 43 cm3 were associated with
3-year survival rates of 50% and 28%, respective-
ly, p = 0.0002), performance status (3-year survi-
val rates of 48% and 31% for KPS of 100–90% and
80–70%, respectively, p = 0.0006), disease stage
(3-year survival rates of 45% and 22% for stage I
and stage II disease, respectively, p = 0.003) and
weight loss (3-year survival rates of 22% and 40%
for patients with a weight loss of > 10% and the
remaining patients, respectively, p = 0.03). No sta-
tistically significant relationship was demon-
strated between the dose and overall survival, al-
though the 3-year overall survival rates in patients
receiving BED of at least 74 Gy and those receiving
lower doses were 50% and 30%, respectively
(p = 0.1). There was no difference in overall su-
rvival between patients eligible and ineligible for
SBRT (3-year survival rates of 39% and 35%, re-
spectively, p = 0.3). The radiotherapy regimen did
not affect overall survival. Table 3 presents the
detailed results of the univariate analysis with re-
spect to overall survival. Multivariate analysis, in
addition to the factors significantly associated with
survival in the univariate analysis, demonstrated
a significant negative correlation between age abo-
ve 70 years and survival. The results of the multi-
variate analysis in terms of overall survival are
summarised in Table 4.
The estimated 2- and 3-year local progression
free survival rates in the study population were
63% and 50%, respectively. The local progression
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free survival curve for the study population is pre-
sented in Figure 2. In univariate analysis, the fol-
lowing factors significantly improved local control:
a lower GTV (p = 0.002), stage I disease (p = 0.004)
and KPS of 90–100% (p = 0.02). Patients eligible
for SBRT also had a significantly superior local
control with 3-year local progression free survival
rates of 58% compared to 35% in patients ineligi-
ble for SBRT (p = 0.04). The local progression free
survival curves for patients eligible and ineligible
for SBRT are presented in Figure 3. The effect of
the dose, broken down into doses equal to or hi-
gher than median BED (74 Gy) and doses lower
than median BED, on local progression free survi-
val did not reach statistical significance (3-year
local progression free survival rates of 64% and
43%, respectively, p = 0.1). The results of the
multivariate analysis in terms of local progression
free survival are summarised in Table 5.
The estimated 2- and 3-year distant metasta-
sis free survival rates in the study population were
71% and 62%, respectively. This endpoint did not
differ significantly between patients eligible and
ineligible for SBRT. A total of 5 cases of IRR were
identified during the follow-up of 4 to 25 months
(3 cases in the first year after treatment). The 3-year
risk of IRR in the study population was 6%. IRR was
identified in 3 patients eligible for SBRT (5%) and
in 2 patients from the remaining group (4%). Two
patients with IRR received elective irradiation of the
mediastinum and in 3 cases radiotherapy was li-
mited to the tumour with the margin.
Table 3. Overall survival: results of the univariate analysis
Factor Three-year overall survival rate p-value
Gross tumor volume (GTV)
< 43 cm3 (median) 50%
≥ 43 cm3 (median) 28% 0.0002
Karnofsky performance status (KPS)
100%–90% 48%
80%–70% 31% 0.0006
Clinical stage
I 45%
II 22% 0.003
Weight loss in the previous 6 months
< 5% 40%
≥ 5% 21% 0.03
Sex
Female 50%
Male 35% 0.05
Histology
Squamous 68%
Adenocarcinoma 42%
Non-small cell without further specification 28%
No histology 50% 0.1
Age (years)
£ 70 46%
> 70 31% 0.1
Biologically equivalent dose (BED)
< 74 Gy (median) 30%
≥ 74 Gy (median) 50% 0.1
Meeting inclusion criteria for SBRT
Yes 40%
No 38% 0.32
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Table 4. The multivariate analysis of factors determining overall survival
Factor Relative risk (RR) of death [95% Level of statistical
confidence interval (CI)] significance
Karnofsky performance status (KPS)
100%–90% RW (RR): 0.42; PU (CI) (0.27–0.68)
80%–70% RW (RR): 1.0 p = 0.0004
Gross tumor volume (GTV)
< 43 cm3 (median) RW (RR): 0.44; PU (CI) (0.28–0.70)
≥ 43 cm3 (median) RW (RR): 1.0 p = 0.005
GTV as a continuous variable RW (RR): 1.004 (cm3); PU (CI) (1.001–1.007) p = 0.02
Clinical stage
I RW (RR): 0.48; PU (CI) (0.30–0.78)
II RW (RR): 1.0 p = 0.003
Weight loss
≥ 10% RW (RR): 2.36; PU (CI) (1.25–4.45)
< 10% RW (RR): 1.0 p = 0.008
Age (years)
> 70 RW (RR): 1.82; PU (CI) (1.15–2.88)
£ 70 RW (RR): 1.0 p = 0.01
Figure 2. Local progression free survival for all patients Figure 3. Local progression free survival for patients who met criteria
of inclusion for SBRT and the remainder
Discussion
Our results for overall survival and local con-
trol following treatment with 3D-CRT in patients
with early-stage NSCLC are similar to the results
reported in the literature [5]. However, after selec-
ting patients with tumour characteristics consistent
with tumour characteristics in patients included
in studies investigating SBRT in lung cancer, we
observed a superior local control than in the re-
maining patients, without any differences in su-
rvival. Due to the retrospective nature of our stu-
dy it is difficult to reliably establish whether the
severity of co-morbidities in this group was higher
than in the remaining patients. It may, however,
be assumed that patients with small peripheral
tumours who undergo radiotherapy have more
contraindications for surgery than patients with
larger central tumours. This could have affected the
lack of differences in survival between the groups
despite a superior local control in the group of
patients potentially eligible for SBRT. The supe-
rior local control in the group of patients eligible
for SBRT is associated with lower tumour volumes
in this group. Low tumour volume was the stron-
gest positive prognostic factor in our study, both
in terms of local control and overall survival. Many
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papers have been published to confirm the negati-
ve effect of larger volumes of the lesions (tumour
and involved lymph nodes — GTV) on survival in
patients with NSCLC treated with radiotherapy
[12–16].
Despite the relatively small tumour volumes
in the group of patients eligible for SBRT, the de-
monstrated local control in this group (updated 3-
year local progression free survival rate of 58%) is
much worse than that in SBRT, in which case the
3-year local control rate, defined similarly to us as
absence of disease progression, is 80–100% [6]. The
doses given using the SBRT technique, especially
in cases of peripheral tumours, are equivalent to
biological doses exceeding 100 Gy and are there-
fore equivalent to doses that are much higher than
the dose range used in our study (BED: 58–82 Gy).
No effect of dose on outcomes within the employ-
ed dose ranges was shown. Martel et al. [17] sug-
gest that doses necessary to cure NSCLC should
exceed 84 Gy. This largely explains the difference
in outcomes between 3D-CRT and SBRT. With 3D-
CRT, administration of such high doses is difficult
due to a lower conformality index (the dose decre-
ase outside the treated tumour). Conventional frac-
tionation, which is most commonly associated with
using 3D-CRT, also leads to the prolongation of
treatment duration, which results in decreased tre-
atment efficacy when attempts to escalate the dose
using this technique are made [18]. Shortening of
the treatment duration is a factor that increases the
biological efficacy of radiotherapy and, at the same
time, by shortening the time spent by the patient
travelling to the related radiotherapy sessions or
hospitalisations, makes the treatment more com-
fortable and less expensive for the population of
elderly and otherwise unwell patients. For this
reason, at our centre, we used accelerated hypo-
fractionated radiotherapy. The study regimen was
taken from a study by Slotman et al. [19], who de-
livered 48 Gy in 12 fractions. The good tolerabili-
ty of the treatment made it possible to increase the
dose, with time, to 52 Gy in 13 fractions. The out-
comes observed using this regimen are no different
from those observed with conventionally fractio-
nated radiotherapy regimens, although do not re-
sult in outcomes possible thanks to SBRT. Treat-
ment with SBRT should be the treatment of cho-
ice for patients who are eligible for this method.
Our study has obvious methodological limi-
tations because of its retrospective nature and the
arbitrary division of patients into those eligible and
those ineligible for SBRT. In real life, many other
patient- and tumour-related factors would affect
patient assignment to the two treatment groups. In
addition, the outcomes of SBRT are often based on
short follow-up periods and early development of
fibrosis following a high dose of SBRT may confo-
und the evaluation of local control, hence the out-
comes may be worse than those reported in the li-
terature. Similar objections may be raised with
reference to our study, where the median follow-
up period was 30 months and the assessment of
local control was based on the absence of radio-
logical progression. Despite that the outcomes
were still inferior to those obtained using SBRT.
SBRT seems to be an appropriate method of tre-
atment intensification in a population of patients
ineligible for surgery, such as patients with mul-
tiple co-morbidities and often elderly patients,
as this method is characterised by low toxicity
provided that the tumours are appropriately qu-
alified for the treatment [20]. All the other forms
of treatment intensification, such as radiochemo-
therapy or alternative fractionation regimens,
failed to improve the outcomes in this group of
patients compared to conventional radiotherapy
alone [21].
Table 5. The multivariate analysis of factors determining local progression free survival
Factor Relative risk (RR) of death [95% Level of statistical
confidence interval (CI)] significance
Karnofsky performance status (KPS)
100%–90% RW (RR): 0.46; PU (CI) (0.24–0.82)
80%–70% RW (RR): 1.0 p = 0.01
Clinical stage
I RW (RR): 0.47; PU (CI) (0.25–0.88)
II RW (RR): 1.0 p = 0.02
Gross tumor volume (GTV)
GTV as a continuous variable RW (RR): 1.004 (cm3);
PU (CI) (1.001–1.007) p = 0.04
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The main type of failure in our study was local
recurrence, which is consistent with the results of
all the studies investigating radiotherapy in patients
with NSCLC. Isolated mediastinal nodal recurren-
ces were rare, which justifies the generally adopted
approach to skip elective mediastinal irradiation in
early-stage NSCLC [22]. Furthermore, the inciden-
ce of this failure was not reduced by using elective
irradiation. Three out of 5 isolated regional recur-
rences developed within the first year after treat-
ment. Only a few patients in the study population
had undergone PET-CT prior to radiotherapy, which
could have led to unsatisfactory outcomes. One of
our prospective studies of 100 patients demonstra-
ted that PET-CT before radical radiotherapy plan-
ning led to disqualification of 25% of patients from
treatment, while in 27% of patients eventually con-
sidered eligible for radiotherapy, the irradiation field
was modified following the PET-CT scan due to the
identification of additional pathological lesions [23].
This is most likely another potential method to im-
prove the outcomes of radiotherapy, also in patients
with early-stage NSCLC.
Conclusions
The retrospective nature of our study limits
the conclusions. However, in view of the absence
of prospective studies of 3D-CRT in patients eligi-
ble for SBRT, it seems that based on our results the
following practical conclusion may be drawn: gi-
ven the poorer local control following 3D-CRT
compared to the known outcomes of SBRT repor-
ted in the literature, patients with early-stage
NSCLC who are ineligible for surgery but who are
eligible for SBRT should be offered treatment with
SBRT rather than with 3D-CRT.
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